Upgrade to SI Premium - Free Trial

Kymera Therapeutics (KYMR)

111.46 -1.91 (1.68%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/31/26)

Latest Headlines

Kymera Therapeutics (KYMR) PT Raised to $140 at Mizuho July 16, 2026 5:29 AM - StreetInsider Kymera Therapeutics (KYMR) call put ratio 1 call to 3.3 puts with a focus on December 95 and 100 puts as share price down 8% July 13, 2026 2:07 PM - StreetInsider Form 4 Kymera Therapeutics, For: Jul 07 Filed by: Mainolfi Nello July 7, 2026 8:01 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Mainolfi Nello July 7, 2026 4:07 PM - SEC Filing Kymera Therapeutics names ex-Sanofi executive to lead KT-621 program July 7, 2026 7:00 AM - StreetInsider Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader July 7, 2026 7:00 AM - Globe NewsWire Form 4 Kymera Therapeutics, For: Jul 01 Filed by: Goodman Noah July 2, 2026 6:30 PM - SEC Filing Form 4 Kymera Therapeutics, For: Jun 30 Filed by: Jacobs Bruce N. July 2, 2026 6:30 PM - SEC Filing Form 4 Kymera Therapeutics, For: Jul 01 Filed by: Mainolfi Nello July 2, 2026 6:30 PM - SEC Filing Form 4/A Kymera Therapeutics, For: Jun 26 Filed by: Booth Bruce July 2, 2026 5:39 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Mainolfi Nello July 2, 2026 8:33 AM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Goodman Noah July 1, 2026 4:58 PM - SEC Filing Form 4 Kymera Therapeutics, For: Jun 26 Filed by: Booth Bruce June 30, 2026 5:32 PM - SEC Filing Form 4 Kymera Therapeutics, For: Jun 26 Filed by: Booth Bruce June 30, 2026 5:30 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Jacobs Bruce N. June 30, 2026 4:33 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P. June 29, 2026 5:52 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P. June 29, 2026 5:51 PM - SEC Filing Kymera Therapeutics (KYMR) PT Raised to $155 at B.Riley June 29, 2026 8:30 AM - StreetInsider Kymera Therapeutics (KYMR) PT Raised to $136 at Truist Securities June 29, 2026 7:12 AM - StreetInsider Form 4 Kymera Therapeutics, For: Jun 26 Filed by: BVF II GP LLC June 26, 2026 6:48 PM - SEC Filing Form SCHEDULE 13D/A Kymera Therapeutics, Filed by: BIOTECHNOLOGY VALUE FUND L P June 26, 2026 6:44 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: BVF PARTNERS L P/IL June 26, 2026 6:13 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P. June 26, 2026 4:52 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P. June 26, 2026 4:52 PM - SEC Filing Kymera Therapeutics (KYMR) PT Raised to $136 at Truist Securities June 26, 2026 8:08 AM - StreetInsider Kymera Therapeutics (KYMR) PT Raised to $129 at Canaccord June 26, 2026 7:37 AM - StreetInsider Kymera Therapeutics (KYMR) PT Raised to $155 at B.Riley June 26, 2026 6:57 AM - StreetInsider Form 4 Kymera Therapeutics, For: Jun 23 Filed by: Booth Bruce June 25, 2026 9:56 PM - SEC Filing Form 4 Kymera Therapeutics, For: Jun 23 Filed by: Booth Bruce June 25, 2026 9:55 PM - SEC Filing Form 4 Kymera Therapeutics, For: Jun 24 Filed by: BVF II GP LLC June 25, 2026 6:58 PM - SEC Filing Form 4 Kymera Therapeutics, For: Jun 25 Filed by: Goodman Noah June 25, 2026 6:00 PM - SEC Filing Form 4 Kymera Therapeutics, For: Jun 24 Filed by: Hrustanovic Gorjan June 25, 2026 6:00 PM - SEC Filing Form 4 Kymera Therapeutics, For: Jun 24 Filed by: Albers Jeffrey W. June 25, 2026 6:00 PM - SEC Filing Form 4 Kymera Therapeutics, For: Jun 24 Filed by: Booth Bruce June 25, 2026 6:00 PM - SEC Filing Form 4 Kymera Therapeutics, For: Jun 24 Filed by: Esposito Pamela June 25, 2026 6:00 PM - SEC Filing Form 4 Kymera Therapeutics, For: Jun 24 Filed by: MARAGANORE JOHN June 25, 2026 6:00 PM - SEC Filing Form 4 Kymera Therapeutics, For: Jun 24 Filed by: Sandor Victor June 25, 2026 6:00 PM - SEC Filing Form 4 Kymera Therapeutics, For: Jun 24 Filed by: Ridloff Elena June 25, 2026 6:00 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P. June 25, 2026 5:26 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P. June 25, 2026 5:25 PM - SEC Filing Form 4 Kymera Therapeutics, For: Jun 24 Filed by: 667, L.P. June 25, 2026 5:11 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Goodman Noah June 25, 2026 4:27 PM - SEC Filing Form 8-K Kymera Therapeutics, For: Jun 25 June 25, 2026 7:11 AM - SEC Filing Kymera completes Phase 2b AD trial enrollment ahead of schedule June 25, 2026 7:02 AM - StreetInsider Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026 June 25, 2026 7:00 AM - Globe NewsWire Form 144 Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P. June 24, 2026 5:30 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P. June 24, 2026 5:29 PM - SEC Filing Form 8-K Kymera Therapeutics, For: Jun 24 June 24, 2026 4:08 PM - SEC Filing Kymera Therapeutics names Felix Baker as board chairman June 24, 2026 4:01 PM - StreetInsider Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors June 24, 2026 4:01 PM - Globe NewsWire Form 144 Kymera Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P. June 23, 2026 6:14 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P. June 23, 2026 6:14 PM - SEC Filing Form 4 Kymera Therapeutics, For: Jun 17 Filed by: Booth Bruce June 22, 2026 9:02 PM - SEC Filing Form 4 Kymera Therapeutics, For: Jun 17 Filed by: Booth Bruce June 22, 2026 9:01 PM - SEC Filing Form 4 Kymera Therapeutics, For: Jun 22 Filed by: Goodman Noah June 22, 2026 5:47 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P. June 22, 2026 5:29 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P. June 22, 2026 5:28 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Goodman Noah June 22, 2026 4:47 PM - SEC Filing Truist Securities Reiterates Buy Rating on Kymera Therapeutics (KYMR) Following Sector Deal June 22, 2026 11:24 AM - StreetInsider Form 144 Kymera Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P. June 18, 2026 5:36 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P. June 18, 2026 5:36 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P. June 17, 2026 5:26 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P. June 17, 2026 5:26 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Booth Bruce June 17, 2026 5:25 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Chadwick Jeremy G June 17, 2026 4:43 PM - SEC Filing Kymera presents phase 1 data for KT-621 in healthy Japanese adults June 12, 2026 7:00 AM - StreetInsider Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting June 12, 2026 7:00 AM - Globe NewsWire Kymera begins phase 1 trial of KT-485, receives $20M from Sanofi June 9, 2026 7:00 AM - StreetInsider Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration June 9, 2026 7:00 AM - Globe NewsWire Form 8-K Kymera Therapeutics, For: Jun 05 June 8, 2026 4:05 PM - SEC Filing Kymera Therapeutics names Penny Carlson development operations head June 8, 2026 4:01 PM - StreetInsider Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations June 8, 2026 4:01 PM - Globe NewsWire Kymera Therapeutics (KYMR) PT Raised to $97 at Brookline Capital Markets June 8, 2026 1:05 PM - StreetInsider Kymera presents preclinical lupus data for oral IRF5 degrader KT-579 June 8, 2026 7:00 AM - StreetInsider Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses June 8, 2026 7:00 AM - Globe NewsWire Form 4 Kymera Therapeutics, For: Jun 02 Filed by: Jacobs Bruce N. June 3, 2026 7:30 AM - SEC Filing Form 4 Kymera Therapeutics, For: May 26 Filed by: Chadwick Jeremy G May 27, 2026 5:51 PM - SEC Filing Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference May 27, 2026 7:00 AM - Globe NewsWire Form 144 Kymera Therapeutics, Filed by: Chadwick Jeremy G May 26, 2026 4:42 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Chadwick Jeremy G May 26, 2026 4:05 PM - SEC Filing Form 4 Kymera Therapeutics, For: May 19 Filed by: Esposito Pamela May 19, 2026 4:05 PM - SEC Filing Form 4 Kymera Therapeutics, For: May 18 Filed by: Jacobs Bruce N. May 19, 2026 7:30 AM - SEC Filing Form SCHEDULE 13G Kymera Therapeutics, Filed by: T. Rowe Price Investment Management, Inc. May 15, 2026 10:07 AM - SEC Filing Form SCHEDULE 13G/A Kymera Therapeutics, Filed by: WELLINGTON MANAGEMENT GROUP LLP May 15, 2026 7:49 AM - SEC Filing Kymera to present KT-621 data at dermatology and lung conferences May 15, 2026 7:00 AM - StreetInsider Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses May 15, 2026 7:00 AM - Globe NewsWire Form 4 Kymera Therapeutics, For: May 11 Filed by: Ridloff Elena May 11, 2026 4:59 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Ridloff Elena May 11, 2026 4:36 PM - SEC Filing Form SCHEDULE 13G/A Kymera Therapeutics, Filed by: FMR LLC May 6, 2026 11:24 AM - SEC Filing Kymera Therapeutics to Participate in Upcoming May Investor Conferences May 6, 2026 7:00 AM - Globe NewsWire Canaccord Starts Kymera Therapeutics (KYMR) at Buy May 6, 2026 5:09 AM - StreetInsider Kymera presents preclinical IBD data for oral IRF5 degrader KT-579 May 5, 2026 7:01 AM - StreetInsider Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week May 5, 2026 7:00 AM - Globe NewsWire Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent May 5, 2026 6:37 AM - BizWire Kymera Therapeutics (KYMR) PT Lowered to $119 at Morgan Stanley April 30, 2026 12:01 PM - StreetInsider Form 10-Q Kymera Therapeutics, For: Mar 31 April 30, 2026 7:16 AM - SEC Filing Form 8-K Kymera Therapeutics, For: Apr 30 April 30, 2026 7:10 AM - SEC Filing Kymera Therapeutics (KYMR) Tops Q1 EPS by 17c April 30, 2026 7:05 AM - StreetInsider Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update April 30, 2026 7:00 AM - Globe NewsWire Form 4 Kymera Therapeutics, For: Apr 29 Filed by: Mainolfi Nello April 29, 2026 5:00 PM - SEC Filing Form ARS Kymera Therapeutics, For: Dec 31 April 29, 2026 4:17 PM - SEC Filing Form DEFA14A Kymera Therapeutics, April 29, 2026 4:12 PM - SEC Filing Form 144 Kymera Therapeutics, Filed by: Mainolfi Nello April 29, 2026 4:09 PM - SEC Filing Form DEF 14A Kymera Therapeutics, For: Jun 24 April 29, 2026 4:06 PM - SEC Filing Form 4 Kymera Therapeutics, For: Apr 22 Filed by: Booth Bruce April 24, 2026 4:34 PM - SEC Filing Form 4 Kymera Therapeutics, For: Apr 22 Filed by: Chadwick Jeremy G April 24, 2026 4:31 PM - SEC Filing Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026 April 23, 2026 7:02 AM - Globe NewsWire Full Article List